Nipro : Notice on Establishment of US Holding company and Reorganization of Subsidiaries in the Americas








January 11, 2022

NIPRO CORPORATION

Notice on Establishment of US Holding company and

Reorganization of Subsidiaries in the Americas

As stated in the “Notice on Establishment of the Preparatory Office for US Holding company and Reorganization of US Subsidiaries” released on April 1, 2020, Nipro had established a preparatory office for setting up its US Holding company in Miami, Florida, USA, and was working to set up a company that controls our business entities located in the Americas in order to promote further expansion of our global business and enhance regional strategy. We hereby announce that we have established a US Holding company and reorganized our subsidiaries located in the Americas.

1. Purpose of establishing the Holding company and reorganizing subsidiaries

Nipro already has Holding company established in Europe and China. In the United States, we newly established Nipro Holding Americas, Inc. as our US Holding company, with the primary purpose of promoting business development appropriate for local circumstances, swift decision-making, and strengthening the business management system, and reorganized our subsidiaries located in the Americas.

In addition to the above, the new Holding company will integrate fund management of US subsidiaries under its control to improve management efficiency while providing shared services for operations such as accounting and human resources management, helping to optimize operations of the entire Group.

2. Outline of Reorganization of Subsidiaries

  1. Outline of reorganization

On August 24, 2021, Nipro Holding Americas (NHA) was established as a wholly owned subsidiary of the Company.

On January 1, 2022, the Company transferred the shares of Nipro Medical Corporation (NMC) and the subsidiaries consolidated under NMC to NHA.

(2) Overview of the Holding company

(1)

Name

Nipro Holding Americas, Inc.

(2)

Location

Miami, Florida, USA

(3)

Title and name of representative

Goichi Miyazumi, President

(4)

Business outline

Supervision of new investments and fund

management of local subsidiaries in the

Americas and support for management

operations, new business promotion, etc.

(5)

Capital

$1 USD

(6)

Date of establishment

August 24, 2021

(7)

Major shareholder and its ownership ratio

Nipro Corporation 100%

(8)

Fiscal year end

December 31

  1. Subsidiaries subject to reorganization [Medical-related business]
    • Nipro Medical Corporation
      1. Established: March 7, 1996
      2. Major shareholder and its ownership ratio: Before transfer: Nipro 100% After transfer: Nipro Holdings Americas 100%
      3. Business outline: Sales of medical devices
      4. Location: Florida, USA
    • Avantec Vascular Corporation
      1. Established: December 20, 1999
      2. Major shareholder and its ownership ratio: Before transfer: NMC 100% After transfer: NHA 100%
      3. Business outline: Development of medical devices
      4. Location: California, USA
    • Infraredx, Inc.
      1. Established: November 16, 1999
      2. Major shareholder and its ownership ratio: Before transfer: NMC 100% After transfer: NHA 100%
      3. Business outline: Manufacture and sales of medical devices
      4. Location: Massachusetts, USA
    • New England Cell Therapeutics, Inc.
      1. Established: November 15, 2019
      2. Major shareholder and its ownership ratio: Before transfer: NMC 100% After transfer: NHA 100%
      3. Business outline: Research and development, manufacturing and sales of regenerative medicine products
      4. Location: Connecticut, USA
    • Nipro Medical Ltda.
      1. Established: August 17, 1995
      2. Major shareholder and its ownership ratio: Before transfer: NMC 100%

After transfer: NHA 100%

    1. Business outline: Manufacture of medical devices
    2. Location: Sao Paulo, Brazil
  • Salbego Laboratorio Farmaceutico Ltda.
    1. Established: June 27, 1989
    2. Major shareholder and its ownership ratio: Before transfer: NMC 100% After transfer: NHA 100%
    3. Business outline: Manufacture of dialysate
    4. Location: Rio Grande do Sul, Brazil

[Pharma packaging business]

  • Nipro PharmaPackaging Americas Corp.
    1. Established: July 7, 2011
    2. Major shareholder and its ownership ratio: Before transfer: NMC 100% After transfer: NHA 100%
    3. Business outline: Manufacture and sales of medical glass products
    4. Location: New Jersey, USA

3 Impact on business results

The impact of the transfer of shares, etc. associated with the establishment of the Holding company on the business results for the current fiscal year is insignificant.

Publicnow 2022

All news about NIPRO CORPORATION

Sales 2022 490 B
4 249 M
4 249 M
Net income 2022 14 698 M
127 M
127 M
Net Debt 2022 457 B
3 963 M
3 963 M
P/E ratio 2022 11,9x
Yield 2022 2,79%
Capitalization 175 B
1 521 M
1 518 M
EV / Sales 2022 1,29x
EV / Sales 2023 1,22x
Nbr of Employees 35 251
Free-Float


Duration :


Period :



Nipro Corporation Technical Analysis Chart | MarketScreener

Technical analysis trends NIPRO CORPORATION

Short Term Mid-Term Long Term
Trends Neutral Bearish Bearish



Income Statement Evolution

Sell

Buy

Mean consensus HOLD
Number of Analysts 3
Last Close Price
1 074,00 JPY
Average target price
1 310,00 JPY
Spread / Average Target 22,0%




Source link

Leave a Comment

Your email address will not be published. Required fields are marked *